(Q36092026)

12 August 2017

Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer (English)

1 reference

triple-negative breast cancer

12 August 2017

1 reference

1 reference

Jeong Eun Kim

1

1 reference

12 August 2017

Heui June Ahn

2

1 reference

12 August 2017

Jin-Hee Ahn

3

1 reference

12 August 2017

Dok Hyun Yoon

4

1 reference

12 August 2017

Sung-Bae Kim

5

1 reference

12 August 2017

Kyung Hae Jung

6

1 reference

12 August 2017

Gyung-Yub Gong

7

1 reference

12 August 2017

Mi-Jung Kim

8

1 reference

12 August 2017

Byung Ho Son

9

1 reference

12 August 2017

Sei Hyun Ahn

10

1 reference

12 August 2017

language of work or name

1 reference

28 June 2012

1 reference

12 August 2017

Journal of breast cancer

1 reference

12 August 2017

15

1 reference

12 August 2017

2

1 reference

12 August 2017

197-202

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

12 August 2017

start time

1 January 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Patterns of recurrence after breast-conserving treatment for early stage breast cancer by molecular subtype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Triple-negative breast cancer: clinical features and patterns of recurrence

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Hallmarks of 'BRCAness' in sporadic cancers

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Subtypes of breast cancer show preferential site of relapse

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Recurrence and survival rates among early breast cancer cases with triple negative immunophenotype

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395743

Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

23 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22807937

12 December 2020

inferred from PubMed ID database lookup

Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22807937

12 December 2020

inferred from PubMed ID database lookup

Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22807937

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.4048/JBC.2012.15.2.197

1 reference

release_2j4gclibszhafgaboejmbr26pu

12 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2j4gclibszhafgaboejmbr26pu

24 November 2022

mapped directly with Wikidata item

1 reference

12 August 2017

PubMed publication ID

22807937

1 reference